MedTrace Logo

Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy

NCT05138757 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-09

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to gather information on the safety and efficacy of using a prebiotic as an adjunctive therapy to peanut oral immunotherapy. The prebiotic is not an FDA approved drug or medication rather a fiber found at local grocery stores.

Conditions

Interventions

DRUG

Prebiotic

A prebiotic is a purified fiber of plant origin that has digestive health benefits by fostering the growth of beneficial microbes.

DRUG

Placebo

A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Christina E Ciaccio, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2025-03-12
Completion
2025-03-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05138757 on ClinicalTrials.gov